Otsuji E, Yamaguchi T, Yamaoka N, Taniguchi K, Kato M, Kotani T, Kitamura K, Takahashi T
First Department of Surgery, Kyoto Prefectural University of Medicine.
Jpn J Cancer Res. 1994 May;85(5):530-5. doi: 10.1111/j.1349-7006.1994.tb02391.x.
In this study, we conjugated chimeric Fab fragments of the monoclonal antibody (MAb) A7, which reacts with pancreatic cancers, to the antitumor drug neocarzinostatin (chA7Fab-NCS) and intravenously injected 125I-labeled chA7Fab-NCS into nude mice bearing a human pancreatic cancer xenograft. We compared the tumor localization of 125I-labeled chA7Fab-NCS with that of conventional 125I-labeled A7-NCS, which was produced by conjugation of MAb A7 and NCS. 125I-Labeled chA7Fab-NCS accumulated in the tumor earlier than 125I-labeled A7-NCS, and significantly larger amounts of 125I-labeled chA7Fab-NCS had accumulated in the tumor 1 hour after injection. The results suggest that chA7Fab may be a suitable carrier for NCS in immunotargeting therapy against pancreatic cancer.
在本研究中，我们将与胰腺癌发生反应的单克隆抗体（MAb）A7的嵌合Fab片段与抗肿瘤药物新制癌菌素（chA7Fab-NCS）偶联，并将125I标记的chA7Fab-NCS静脉注射到携带人胰腺癌异种移植瘤的裸鼠体内。我们将125I标记的chA7Fab-NCS的肿瘤定位与通过MAb A7和NCS偶联产生的传统125I标记的A7-NCS的肿瘤定位进行了比较。125I标记的chA7Fab-NCS比125I标记的A7-NCS更早地在肿瘤中蓄积，并且在注射后1小时，大量的125I标记的chA7Fab-NCS已在肿瘤中蓄积。结果表明，chA7Fab可能是新制癌菌素在胰腺癌免疫靶向治疗中合适的载体。
